Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-011206
Filing Date
2025-05-16
Accepted
2025-05-16 13:49:23
Documents
64
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 803628
2 EX-31.1 ex31-1.htm EX-31.1 12355
3 EX-31.2 ex31-2.htm EX-31.2 9290
4 EX-32.1 ex32-1.htm EX-32.1 5900
5 EX-32.2 ex32-2.htm EX-32.2 6703
  Complete submission text file 0001641172-25-011206.txt   4570280

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE rgbp-20241231.xsd EX-101.SCH 38195
7 XBRL CALCULATION FILE rgbp-20241231_cal.xml EX-101.CAL 48157
8 XBRL DEFINITION FILE rgbp-20241231_def.xml EX-101.DEF 172370
9 XBRL LABEL FILE rgbp-20241231_lab.xml EX-101.LAB 310279
10 XBRL PRESENTATION FILE rgbp-20241231_pre.xml EX-101.PRE 265809
66 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 616058
Mailing Address 4700 SPRING ST #304 LA MESA CA 91942
Business Address 4700 SPRING ST #304 LA MESA CA 91942 619-722-5505
Regen BioPharma Inc (Filer) CIK: 0001589150 (see all company filings)

EIN.: 455192997 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 333-191725 | Film No.: 25958291
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)